Background: Inflammatory mechanisms of ulcerative colitis (UC) and irritable bowel syndrome (IBS) may overlap or are part of different spectrums. However, potential links between inflammation and IBS-like symptoms in these patient groups are still unclear. The aim of this study was to determine if the systemic inflammatory protein (SIP) profiles differ between UC patients, with presence of inflammation or in remission with or without IBS-like symptoms, and IBS patients.
Methods: Serum from patients with active UC (UCA), UC patients in remission with or without IBS-like symptoms (UCR + IBS, UCR-IBS), IBS patients (IBS), and healthy subjects (HS) was analyzed using the ProSeek Multiplex Inflammation kit, which detects 92 proteins.
Results: The exploratory cohort consisted of 166 subjects (UCA, n = 40; UCR-IBS, n = 45; UCR + IBS, n = 20; IBS, n = 40; HS, n = 21). Systemic inflammatory protein profiles separated UC from non-UC (HS and IBS) patients in multivariate analysis, revealing caspase 8, axin 1, sulfotransferase 1A1, and tumor necrosis factor superfamily member 14 as the variables most important to clustering. Although minor differences were detected between UCR + IBS and UCR-IBS, SIP profiles discriminated UCA from UCR, and interleukin (IL) 17C, IL17A, chemokine ligand 9, and transforming growth factor-α characterized active inflammation. SIP profiles weakly discriminated HS from IBS, although fibroblast growth factor 21 and IL6 serum levels were higher in IBS. Results were confirmed in a validation cohort (UCA, n = 15; UCR + IBS, n = 9; IBS, n = 14).
Conclusions: SIP profiles distinguish UC patients from IBS patients, irrespective of inflammation or IBS-like symptoms, suggesting that inflammatory mechanisms of the diseases are part of different spectrums.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216771 | PMC |
| http://dx.doi.org/10.1093/ibd/izz322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Agonists of the opioid δ-receptor improve irritable bowel syndrome-like symptoms via the central nervous system.
Br J Pharmacol
December 2024
Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Background And Purpose: Irritable bowel syndrome (IBS) is a common condition that is challenging to treat, and novel drugs are needed for this condition. Previously, a chronic vicarious social defeat stress (cVSDS) mouse model exhibits IBS-like symptoms. Also agonists of the opioid δ-receptor exert anti-stress effects in rodents with minimal adverse effects.
View Article and Find Full Text PDFImplication of the enteric glia in the IBS-like colonic inflammation associated with endometriosis.
BMC Womens Health
December 2024
Department of Basic Sciences - Physiology Division, Ponce Health Sciences University, Ponce Research Institute, PO Box 7004, Ponce, 00732-7004, PR, Puerto Rico.
Background: Endometriosis is a complex gynecological disorder characterized by the ectopic growth of endometrial tissue. Symptoms of endometriosis are known to impair the quality of life of patients, and among these are found dysmenorrhea, chronic pelvic pain, and gastrointestinal (GI) issues. GI issues such as painful bowel movements, bloating and constipation or diarrhea, are one of the common reasons for misdiagnosis with irritable bowel syndrome (IBS).
View Article and Find Full Text PDFLateral periaqueductal gray participate in the regulation of irritable bowel syndrome induced by chronic restraint stress.
Neurobiol Dis
December 2024
Central Hospital of Hengyang City, Hengyang 421200, Hunan, China. Electronic address:
Irritable bowel syndrome (IBS) is a functional bowel disorder defined by recurrent abdominal pain, coupled with irregular bowel habits and alterations in the frequency as well as the consistency of stool. At present, IBS is considered as a disease of gut-brain interaction, and an increasing number of studies are focusing on the brain-gut axis. However, the brain regions associated with IBS have not been fully studied yet.
View Article and Find Full Text PDFUnveiling the efficacy of paroxetine and gabapentin in ulcerative colitis patients in remission with co-existing IBS-like symptoms: a single-blinded randomized clinical trial.
Front Med (Lausanne)
November 2024
Department of Psychiatry, Taleghani Hospital, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Article Synopsis
- This clinical trial investigated how effective paroxetine and gabapentin are at improving gastrointestinal symptoms, mental health, and overall quality of life in patients with ulcerative colitis during remission.
- A total of 97 patients were divided into two groups: one received paroxetine (20 mg/day) and the other gabapentin (100 mg increasing to 300 mg over three months), with assessments conducted over three months.
- Results showed that patients taking paroxetine experienced significantly greater reductions in anxiety and depression, as well as improved quality of life, compared to those taking gabapentin.
Recent advances in clinical practice: mastering the challenge-managing IBS symptoms in IBD.
Gut
November 2024
Gastroenterology and Hepatology, KU Leuven University Hospitals Leuven Gasthuisberg Campus Hospital Pharmacy, Leuven, Belgium
Article Synopsis
- * These IBS-like symptoms significantly reduce quality of life and lead to higher healthcare usage, making accurate diagnosis and treatment essential.
- * A comprehensive approach is recommended for treatment, addressing not only inflammation but also including evidence-based pharmacological options, lifestyle changes, and consideration of psychological factors to improve overall patient care.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!